Get started
Author

Paramita Paramita Saha-Chaudhuri

Observed name: Paramita Saha-Chaudhuri
Observed institutions: Sanofi (France), Sanofi (Canada)
OpenAlex ID: A5125578146
Concurrent Improvement in Nasal Polyp Score and Forced Expiratory Volume in One Second with Dupilumab vs Omalizumab in Patients with Severe CRSwNP and Coexisting Asthma: Results from the EVEREST Study
2026 · Anju Peters, Brian Lipworth, et al. · Journal of Allergy and Clinical Immunology
Efficacy of dupilumab vs omalizumab in patients with severe chronic rhinosinusitis with nasal polyps coexisting with asthma and allergic rhinitis: Results from the head-to-head, prospective, randomized EVEREST study
2026 · John Oppenheimer, Enrico Heffler, et al. · Journal of Allergy and Clinical Immunology
Dupilumab With Medium-Dose Inhaled Corticosteroids Versus Omalizumab With High-Dose Inhaled Corticosteroids Improves Clinical Outcomes In Patients With Coexisting Chronic Rhinosinusitis With Nasal Polyps And Uncontrolled Asthma
2026 · Martin Wagenmann, Arnaud Bourdin, et al. · Journal of Allergy and Clinical Immunology
PDF
Works count: 3
Citation count:
H-index:
I10-index:
Year
Topic
Type